Abstract
Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A2A agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A2A agonist..
Original language | English (US) |
---|---|
Pages (from-to) | 1123-1130 |
Number of pages | 8 |
Journal | Journal of the American College of Cardiology |
Volume | 54 |
Issue number | 13 |
DOIs | |
State | Published - Sep 22 2009 |
Externally published | Yes |
Keywords
- adenosine
- myocardial perfusion imaging
- regadenoson
- single-photon emission computed tomography
- stress testing
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine